Biomarker & CDx
September 13, 2021

Top 15 NGS Panels for Cancer

Biomarker & CDx
April 10, 2020

Top 15 NGS Panels for Cancer

Author

Each expert team needs a panel, but what makes a panel suited to each lab is unique. We took a look at a large universe of NGS panels to help identify what makes panels great.

Lab directors ask themselves: how do I choose or create the best NGS panel for my laboratory? At the same time, clinical teams ask themselves: what is the best NGS panel to understand biology in a difficult case? Each expert team needs a panel, but what makes a panel suited to each lab is unique.

We took a look at a large universe of panels to help identify what makes panels great. We learned:

3 WAYS TO LOOK AT THE TOP 15:

Cases run: In order for a panel to be widely adopted, it needs to be fully functional at scale. In genomics, this means a panel has run over 100,000 samples. The top three panels based on estimated number of cases are Foundation Medicine’s FoundationOne CDx, Thermo Fisher’s Oncomine Comprehensive, and Illumina’s TruSight Oncology 500. All have FDA clearance currently or are pursuing clearance. These platforms are stable and have robust validation data.

Complete workflow: Academic medical centers are workflow integrators and include physician sign-off. The three major centers still providing independent NGS panel designs included MSKCC, University of Michigan and OHSU. It is our impression from reading company literature, Tempus XT is the only product with a physician signed-off report.

Highest analytical performance: To understand analytical performance, we combined information from 10 attributes into a qualitative performance score (see key terms below for definition). The panels with the best combined scores were Tempus XT, xGen Pan Cancer Panel and TruSight Oncology 500. Quickly on the heels of these developers are Oncomine Comprehensive, MI TurmorSeek and MLabs (University of Michigan). We look forward to the new comprehensive cancer panel from Agilent which should bring their aggregate score into the top cohort.

Image for post

2 INDUSTRY INSIGHTS

Technology developers take different approaches. Roche, Thermo and Illumina are the leading platforms with validated panels. IDT (Integrated DNA Technologies) pursues a differentiation approach by developing high sensitivity assays modules without investing in software tools. Lack of software tools does not hinder assay developers who often use IDT product modules when creating their assays. The developers then build software solutions by customizing open source tools or proprietary software. Agilent takes a third approach by developing a workflow alternative to Thermo and Illumina. It should be noted, Agilent also sells workflow modules separately and this offering has been popular with diagnostics companies such as Gaurdant and PGDx, as well as academic medical centers.

Fewer academic medical centers were in top cohort than expected. This may be due to the preference for running exomes at these centers instead of comprehensive panels or these centers may be running tumor specific panels. An emerging trend is for centers to partner with emerging diagnostic companies for part of their NGS workflow. In January 2020, the Mayo clinic announced they would be collaborating with PGDx. MD Anderson is also experimenting with the PGDx platform and others may follow.

To advance our understanding of this complicated field, we would love to hear your ideas. Do you agree? Did we miss a company or a panel that you think should be in the list? Do you have insights into platforms outside the US that we should include?

Please reach out to us on Facebook or LinkedIn, we are happy to update this study with your feedback.

METHODOLOGY

Universe & Segmentation Strategy: We did market research to analyze a universe of over 3000 panels. Sources we used included the NCBI’s Genetic Test Registry, company websites, publications, webinars and company literature. From this universe we narrowed the analysis to comprehensive cancer panels for liquid and solid tumors; this segment is slightly under 300 panels. From this 300, about 30 panels had significant publicly available information. What is presented are 15 comprehensive panels that are not redundant by institution. This report is biased to US companies and institutions mainly due to the availability of competitive information.

KEY TERMS DEFINED

Cases: samples run on the platform for patient treatment. Total number of samples run on a platform is likely larger than patient cases.

NA: Information not available at time of writing

Performance Score: This is a qualitative ranking from ten scored attributes. Included in the attributes are detection and accuracy for the main classes of variants (SNV, CNV, Indel & Fusions), turn-around-time, completeness. Weakness in the accuracy of this score may be the result of missing information, or missing attributes in score such as uniformity. Furthermore, the scoring model rewards panels designed for high sensitivity applications such as liquid biopsy, panels which have more complete workflows and panels run on-premise and therefore have shorter turn-around-times.

Turn-around-time: Total number of days or weeks to run an assay on a platform or have a sample run in a lab as a service.

Workflow completeness: For this analysis we broke the workflow into four key sections: library prep (LIB), variant calling file (VCF), VCF interpretation (INT) and physician signed-off of report (DR-RPT). We realize that some may critique this segmentation as overly broad. One weakness in this segmentation is it does not distinguish between VCF interpretation and reporting strategies which can be very different; for example an N-of-One interpretation and report vs. a Pierian Dx interpretation and report.

The author is MD Napier, MS, MPhil, MBA. The author was a paid consultant to Larvol Inc. and has over 10 years’ experience in product marketing NGS panels, arrays and software at these major genomics companies: Agilent, Affymetrix and QIAGEN



Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.